Standardized Scalp Cooling Therapy may be Effective in Chemotherapy-Induced Alopecia: Study
A new study published in the Supportive Care in Cancer journal by Liu and colleagues has highlighted that standardized Scalp Cooling Therapy (SCT) significantly reduces chemotherapy-induced alopecia (CIA) among cancer patients. Despite its clinical potential, inconsistent application and lack of standardized guidelines have limited its overall impact. The researchers emphasized that establishing patient-centered and evidence-based protocols for SCT could enhance both clinical outcomes and patient satisfaction.
According to the study, Scalp Cooling Therapy works by reducing blood flow to the hair follicles during chemotherapy, minimizing the absorption of cytotoxic agents and thereby reducing hair loss. The authors noted that while SCT is well-tolerated and effective across multiple cancer types, differences in cooling duration, temperature settings, and equipment design have resulted in varied success rates. By introducing standardized parameters and integrating patient feedback, healthcare providers could ensure greater accessibility and consistent efficacy of this therapy.
The researchers concluded that further investigations are needed to evaluate shorter cooling protocols, portable scalp cooling systems, and pharmacologic adjuncts that can enhance the feasibility and outcomes of SCT. They also stressed the importance of addressing logistical and economic barriers that currently limit its use in routine cancer care. Overall, the study provides strong support for developing uniform clinical guidelines and improving training for oncology teams to make scalp cooling a standard component of supportive cancer treatment.
Keywords:
scalp cooling therapy, chemotherapy-induced alopecia, cancer care, patient-centered treatment, supportive oncology, Supportive Care in Cancer
